Day of reckoning ahead for pay-for-delay deals?

A political consensus seems to be emerging in the Senate Antitrust Subcommittee that negotiated settlements between the makers of brand-name drugs and generics to delay entry into the market are hurting...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

Try FTCWatch FREE for 45 days

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch

Current Issue: 1060
Next Issue: Dec 5, 2023

Browse Archives

In this Issue:

People
Judges balking at defenses about FTC’s constitutionality in preliminary injunction suits
Calendar
GOP antitrust advocate Buck to leave Congress next year
Neil Averitt commentary: Actually using a balancing test in the Google case
Ex-president of asphalt paving firm pleads guilty to rigging bids
On the Shelf: A light touch when regulating misinformation
Consumers ask for data access via app as FTC considers rulemaking
Complaints about robocalls drop to five-year low, FTC finds
Safeguards Rule change set to take effect in April
Tech titans, other companies face PR hurdles in antitrust suits
Google private browsing mode trial taking shape in US as witnesses named
Consider AI, scope of ‘health provider’ in rule update, FTC told
Pfizer-Seagen innovation theory of harm would be difficult for FTC to prove in court
Microsoft likely to argue FTC appeal over Activision deal moot, but agency could press on
Khan declines to recuse in Intuit case
FTC reports increase in elder fraud losses
People
FTC could see more oversight, power when it returns to full strength
Calendar

RSS Feed